Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Drug

Fosun Pharmaceutical’s PD-1 Inhibitor HanSiZhuang Recommended for Approval by EMA’s CHMP

Fineline Cube Sep 23, 2024

Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196), a leading pharmaceutical company in...

Company Deals

Tencent’s We Doctor Partners with CHA on National Digital Health Platform and Academic Initiatives

Fineline Cube Sep 23, 2024

We Doctor, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700) specializing...

Company Deals

Huadong Medicine Secures Exclusive Rights to Janagliflozin for Type 2 Diabetes Treatment in China

Fineline Cube Sep 23, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing...

Policy / Regulatory

Beijing Aims to Establish Rare Disease Drug Security Pilot Zone with ‘White List’ System

Fineline Cube Sep 23, 2024

Beijing is set to follow in the footsteps of Boao Lecheng with the release of...

Policy / Regulatory

Beijing Authorities Release Negative List for Data Export in Key Industries

Fineline Cube Sep 23, 2024

Authorities in Beijing, including the Beijing Municipal Bureau of Commerce and the Beijing Municipal Service...

Company Drug

AstraZeneca’s HIMALAYA Trial Data Showcases Significant Survival Benefits for Liver Cancer Treatment at ESMO 2024

Fineline Cube Sep 22, 2024

At the European Society for Medical Oncology (ESMO) 2024 conference, AstraZeneca (NASDAQ: AZN, LON: AZN)...

Company Drug

Aligos Therapeutics’ ALG-055009 Achieves Positive Topline Results in Phase 2a HERALD Study for MASH

Fineline Cube Sep 21, 2024

Aligos Therapeutics, a clinical-stage biopharmaceutical company focused on liver and viral diseases, has announced positive...

Company Drug

Roche’s Xofluza Receives FDA Approval for Reducing Influenza Transmission in Phase III Study

Fineline Cube Sep 21, 2024

Roche (SWX: ROG; OTCMKTS: RHHBY) has announced that its antiviral drug Xofluza (baloxavir marboxil) has...

Company Drug

J&J’s Rybrevant Secures FDA Approval for EGFR/c-MET Non-Small Cell Lung Cancer Treatment

Fineline Cube Sep 21, 2024

Johnson & Johnson (J&J; NYSE: JNJ)has announced that the US Food and Drug Administration (FDA)...

Company Drug

Beijing’s Apollobio Receives NMPA Approval for HPV Therapeutic Vaccine VGX-3100

Fineline Cube Sep 21, 2024

Beijing’s Apollobio, has announced that the National Medical Products Administration (NMPA) has granted market approval...

Company Drug

Insilico Medicine’s AI-Generated Drug Candidate ISM001-055 Shows Positive Phase II Results in IPF Study

Fineline Cube Sep 20, 2024

China-based artificial intelligence (AI) drug developer Insilico Medicine has reported initial positive data from its...

Company Drug

Lee’s Pharmaceutical’s Zhaoke Ophthalmology Receives NMPA Approval for Generic Lumigan

Fineline Cube Sep 20, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622), has...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ SHR-1701 Combo Therapy for Gastric Cancer Accepted for Review by China’s NMPA

Fineline Cube Sep 20, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

JiCui Cell Therapy Forms Partnership with Fosun Kite to Advance Bispecific CAR-T Cell Therapy Industrialization

Fineline Cube Sep 20, 2024

JiCui Cell Therapy Drug Research Institute, also known as Jiangsu Jicui Juechuang Biotechnology Research Institute...

Company Deals

Apeloa Pharmaceutical Invests in Ji Xing Pharmaceuticals’ Series D Financing Round

Fineline Cube Sep 20, 2024

China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced its participation in the Series D...

Company

CSPC Pharmaceutical Group Appoints Dr. Liu Yongjun as Group CEO and Global R&D President

Fineline Cube Sep 20, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company

Sinopharm Holding Appoints New Chairman and President Following Leadership Changes

Fineline Cube Sep 20, 2024

Sinopharm Holding (HKG: 1099) has announced significant changes in its leadership with the approval of...

Medical Device Policy / Regulatory

China’s NMPA Releases Standards for Brain-Computer Interface Medical Devices

Fineline Cube Sep 20, 2024

The National Medical Products Administration (NMPA) in China has issued a notification confirming the establishment...

Company

Sichuan Kelun-Biotech Reports 32.2% Revenue Growth in 2024 H1, Driven by MSD Partnership

Fineline Cube Sep 20, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced its financial results for the first...

Company Drug

Ocumension Therapeutics’ Zerviate Receives Marketing Approval in China for Allergic Conjunctivitis Treatment

Fineline Cube Sep 19, 2024

Ocumension Therapeutics (HKG: 1477), a leading ophthalmology specialist in China, has announced that its histamine...

Posts pagination

1 … 346 347 348 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.